Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to assess the feasibility and safety of administering intraoperative radiotherapy (IORT) as a boost dur ing breast-conserving surgery (BCS) following neoadjuvant chemotherapy for patients at high risk of breast cancer recurrence. Materials and Methods: Patients who underwent neoadjuvant chemotherapy received a single 20-Gy dose of IORT during BCS, followed by external beam radiotherapy 4–6 weeks after surgery. Results: The median follow-up duration was 31.0 months (range, 18.0–59.0 months). Initial tumor sizes had a median of 2.6 cm (range: 0.8–5.3 cm), reducing to 0.3 cm (range: 0–4.0 cm) after neoadjuvant chemotherapy. The most common neoadjuvant che motherapy regimen was doxorubicin and cyclophosphamide, followed by paclitaxel (n=42, 73.7%). Among 57 patients who re ceived neoadjuvant chemotherapy before BCS and IORT, 2 patients (3.5%) required secondary surgery to achieve negative resec tion margins due to initially positive margins. Regional lymph node irradiation was performed in 37 (64.9%) patients. There was no grade 3 or higher adverse events, with 4 patients (7.0%) experiencing grade 2 acute radiation dermatitis and 3 (5.3%) having less than grade 2 breast edema. Binary correlation analysis did not reveal statistically significant associations between applicator size or radiation therapy modality and the risk of treatment-related toxicity. Furthermore, chi-square analysis showed that the grade of treatment-related toxicity was not associated with the fractionated regimen (p=0.375). Conclusion: Most patients successfully received IORT as a tumor bed boost after neoadjuvant chemotherapy. Thus, IORT may be a safe and feasible option for patients with advanced-stage breast cancer receiving neoadjuvant chemotherapy.
Abstract
Purpose: This study aimed to assess the feasibility and safety of administering intraoperative radiotherapy (IORT) as a boost dur ing breast-conserving surgery (BCS) following neoadjuvant chemotherapy for patients at high risk of breast cancer recurrence. Materials and Methods: Patients who underwent neoadjuvant chemotherapy received a single 20-Gy dose of IORT during BCS, followed by external beam radiotherapy 4–6 weeks after surgery. Results: The median follow-up duration was 31.0 months (range, 18.0–59.0 months). Initial tumor sizes had a median of 2.6 cm (range: 0.8–5.3 cm), reducing to 0.3 cm (range: 0–4.0 cm) after neoadjuvant chemotherapy. The most common neoadjuvant che motherapy regimen was doxorubicin and cyclophosphamide, followed by paclitaxel (n=42, 73.7%). Among 57 patients who re ceived neoadjuvant chemotherapy before BCS and IORT, 2 patients (3.5%) required secondary surgery to achieve negative resec tion margins due to initially positive margins. Regional lymph node irradiation was performed in 37 (64.9%) patients. There was no grade 3 or higher adverse events, with 4 patients (7.0%) experiencing grade 2 acute radiation dermatitis and 3 (5.3%) having less than grade 2 breast edema. Binary correlation analysis did not reveal statistically significant associations between applicator size or radiation therapy modality and the risk of treatment-related toxicity. Furthermore, chi-square analysis showed that the grade of treatment-related toxicity was not associated with the fractionated regimen (p=0.375). Conclusion: Most patients successfully received IORT as a tumor bed boost after neoadjuvant chemotherapy. Thus, IORT may be a safe and feasible option for patients with advanced-stage breast cancer receiving neoadjuvant chemotherapy.
참고문헌 (37)
- Kim S, "An updated nomogram for predicting invasiveness in preoperative ductal carcinoma in situ of the breast", Yonsei Med J, 60, pp.1028~1035 (2019)
- Vaidya JS, "Effect of delayed targeted intraoperative radiotherapy vs wholebreast radiotherapy on local recurrence and survival : long-term results from the TARGIT-A randomized clinical trial in early breast cancer", JAMA Oncol, 6, pp.e200249~ (2020)
- Cho Y, "Intraoperative radiotherapy for resectable pancreatic cancer using a low-energy X-ray source : postoperative complications and early outcomes", Yonsei Med J, 63, pp.405~412 (2022)
- Kolberg HC, "Targeted intraoperative radiotherapy tumour bed boost during breast-conserving surgery after neoadjuvant chemotherapy", Strahlenther Onkol, 193, pp.62~69 (2017)
- Lee JJB, "In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost", Radiat Oncol J, 35, pp.121~128 (2017)
- Hoeller U, "Increasing the rate of late toxicity by changing the score? A comparison of RTOG", EORTC and LENT, Int J Radiat Oncol Biol Phys, pp.2003, 55[DOI]
- Wenz F, "Intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage X-rays : the first 5 years of experience with a novel approach", Int J Radiat Oncol Biol Phys, 77, pp.1309~1314 (2010)
- Herskind C, "Radiobiological aspects of intraoperative radiotherapy(IORT)with isotropic low-energy X rays for early-stage breast cancer", Radiat Res, 163, pp.208~215 (2005)
- Herskind C, "Influence of different dose rates on cell recovery and RBE at different spatial positions during protracted conformal radiotherapy", Radiat Prot Dosimetry, 122, pp.498~505 (2006)
- Herskind C, "Sphere of equivalence—A novel target volume concept for intraoperative radiotherapy using low-energy X rays", Int J Radiat Oncol Biol Phys, 72, pp.1575~1581 (2008)
- Benda RK, "Breast boost : are we missing the target?", Cancer, 97, pp.905~909 (2003)
- Aziz MH, "Can the risk of secondary cancer induction after breast conserving therapy be reduced using intraoperative radiotherapy(IORT)with low-energy X-rays?", Radiat Oncol, 6, pp.174~ (2011)
- Vaidya JS, "Long-term results of targeted intraoperative radiotherapy(Targit)boost during breast-conserving surgery", Int J Radiat Oncol Biol Phys, 81, pp.1091~1097 (2011)
- Blank E, "Single-center long-term follow-up after intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage X-rays", Ann Surg Oncol, 17(Suppl 3), pp.352~358 (2010)
- Burgos-Burgos J, "Hypofractionated whole breast irradiation after IORT treatment : evaluation of acute toxicity and cosmesis", Clin Transl Oncol, 23, pp.179~182 (2021)
- Jambhekar A, "Complication rates after intraoperative radiation therapy : do applicator size and distance to skin matter?", J Surg Res, 268, pp.440~444 (2021)
- Zur M, "Short-term complications of intra-operative radiotherapy for early breast cancer", J Surg Oncol, 113, pp.370~373 (2016)
- Tuschy B, "Clinical aspects of intraoperative radiotherapy in early breast cancer : short-term complications after IORT in women treated with low energy X-rays", Radiat Oncol, 8, pp.95~ (2013)
- Gülçelik MA, "Intraoperative boost radiation effects on early wound complications in breast cancer patients undergoing breast-conserving surgery", Turk J Med Sci, 47, pp.1185~1190 (2017)
- Stoian R, "Intraoperative radiotherapy boost as part of breast-conservation therapy for breast cancer : a single-institution retrospective analysis", Strahlenther Onkol, 197, pp.812~819 (2021)
- Kraus-Tiefenbacher U, "Postoperative seroma formation after intraoperative radiotherapy using low-kilovoltage X-rays given during breastconserving surgery", Int J Radiat Oncol Biol Phys, 77, pp.1140~1145 (2010)
- Broman KK, "Utility of taking additional margins when performing breast-conserving surgery with intraoperative radiation therapy for early breast cancer", World J Surg, 44, pp.3410~3416 (2020)
- Houssami N, "The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy : a meta-analysis", Ann Surg Oncol, 21, pp.717~730 (2014)
- Marinovich ML, "The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy : a meta-analysis", Ann Surg Oncol, 23, pp.3811~3821 (2016)
- Correa C, "Accelerated partial breast irradiation : executive summary for the update of an ASTRO evidence-based consensus statement", Pract Radiat Oncol, 7, pp.73~79 (2017)
- Volders JH, "Neoadjuvant chemotherapy in breast-conserving surgery – Consequences on margin status and excision volumes : a nationwide pathology study", Eur J Surg Oncol, 42, pp.986~993 (2016)
- Devane LA, "The impact of neoadjuvant chemotherapy on margin re-excision in breast-conserving surgery", World J Surg, 44, pp.1547~1551 (2020)
- Wang SL, "Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era : a multicenter, randomized controlled trial from China", J Clin Oncol, 38, pp.3604~3614 (2020)
- Arsenault J, "Acute toxicity and quality of life of hypofractionated radiation therapy for breast cancer", Int J Radiat Oncol Biol Phys, 107, pp.943~948 (2020)
- Shaitelman SF, "Three-year outcomes with hypofractionated versus conventionally fractionated whole-breast irradiation: results of a randomized, noninferiority clinical trial", J Clin Oncol, 36, pp.JCO1800317~ (2018)
- Woodward SG, "Trends in use of hypofractionated whole breast radiation in breast cancer : an analysis of the national cancer database", Int J Radiat Oncol Biol Phys, 109, pp.449~457 (2021)
- Jagsi R, "Disease control after hypofractionation versus conventional fractionation for triple negative breast cancer : comparative effectiveness in a large observational cohort", Int J Radiat Oncol Biol Phys, 112, pp.853~860 (2022)
- Ratosa I, "Hypofractionated radiation therapy for breast cancer : preferences amongst radiation oncologists in Europe – Results from an international survey", Radiother Oncol, 155, pp.17~26 (2021)
- Laucis AM, "The role of facility variation on racial disparities in use of hypofractionated whole breast radiation therapy", Int J Radiat Oncol Biol Phys, 107, pp.949~958 (2020)
- van der Laan HP, "Three-dimensional conformal simultaneously integrated boost technique for breast-conserving radiotherapy", Int J Radiat Oncol Biol Phys, 68, pp.1018~1023 (2007)
- McDonald MW, "Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost", Int J Radiat Oncol Biol Phys, 77, pp.523~530 (2010)
- Murray Brunt A, "Hypofractionated breast radiotherapy for 1 week versus 3 weeks(FAST-forward) : 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial", Lancet, 395, pp.1613~1626 (2020)